Article
Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2026
Di Federico Alessandro, Pecci Federica, Jeng Mark, Peroni Marianna, Marinelli Daniele, Leonetti Alessandro, Stumpo Sara, Mantuano Francesco, Zannini Irene, Gariazzo Eleonora, Makarem Maisam, Pupo Amanda, Lo Bianco Francesca, De Giglio Andrea, de Biase Dario, Altimari Annalisa, Gruppioni Elisa, Minari Roberta, Verzè Michela, Repetto Matteo, Sperandi Francesca, Melotti Barbara, Gelsomino Francesco, Landi Lorenza, Giammaruco Maristella, Scalera Stefano, Cipriani Laura, Maugeri-Saccà Marcello, Calonaci Nicola, Caravagna Giulio, Ricciuti Biagio, Sholl Lynette M, Yang Soo Ryum, LoPiccolo Jaclyn, Rotow Julia K, Awad Mark M, Cappuzzo Federico, Tiseo Marcello, Yu Helena A, Jänne Pasi A, Ardizzoni Andrea
Abstract excerpt
PURPOSE: With rapidly expanding treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), identifying biomarkers that may assist in treatment selection is critical. The impact of EGFR amplification (EGFRAMP) on outcomes to osimertinib is currently unknown. EXPERIMENTAL DESIGN: Patients with metastatic EGFR-mutated NSCLC who received first-line...
Read the complete abstract on PubMedTopics
- Humans